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ABSTRACT
Objectives To determine the extent to which secondary
drugpreventionforpatientswithstrokeinroutineprimary
care varies by sex, age, and socioeconomic
circumstances, and to quantify the effect of secondary
drug prevention on one year mortality by
sociodemographic group.
Design Cohort study using individual patient data from
the health improvement network primary care database.
Setting England.
Participants 12830 patients aged 50 or more years from
113 general practices who had a stroke between 1995
and 2005 and who survived the first 30 days after the
stroke.
Main outcome measures Multivariable associations
between odds of receiving secondary prevention after a
stroke, and sex, age group, and socioeconomic
circumstances; hazard ratios for all cause mortality from
31 days after the stroke and within the first year among
patients receiving treatment and by social group; and
probabilities of one year mortality for social factors of
interest and treatment.
ResultsOnly25.6%ofmenand20.8%ofwomenreceived
secondary prevention. Receipt of secondary prevention
did not vary by socioeconomic circumstances or by sex.
Older patients were, however, substantially less likely to
receive treatment. The adjusted odds ratio for 80-89 year
olds compared with 50-59 year olds was 0.53 (95%
confidence interval 0.41 to 0.69). This was because older
peoplewerelesslikelytoreceivelipidloweringdrugs—for
example, the adjusted odds ratio for 80-89 year olds
compared with 50-59 year olds was 0.44 (95%
confidence interval 0.33 to 0.59). Secondary prevention
was associated with a 50% reduction in mortality risk
(adjustedhazardratio0.50,95%confidenceinterval0.42
to 59). On average, mortality within the first year was
5.7% for patients receiving treatment compared with
11.1% for patients not receiving treatment. There was
little evidence that the effect of treatment differed
between the social groups examined.
Conclusion Under-treatment among older people with
strokeinroutineprimarycarecannotbejustifiedgiventhe
lack of evidence on variations in effectiveness of
treatment by age.
INTRODUCTION
The contribution of medical care to population health
has been a topic of scientific debate for years.
McKeown’s work sparked controversy, but there is
agreement with his claim that clinical interventions
played little part in the decline in mortality before the
mid-20th century.
1 Major advances in medical tech-
nology during the 20th century stimulated a re-exam-
ination of the role of health care in population health.
International studies have focused on coronary heart
disease.Thesesuggestthat50-75%ofthereductionsin
deaths from cardiac causes can be attributed to
improvements in the major risk factors at population
level, particularly smoking but also cholesterol levels
and blood pressure,
2-5 whereas the remaining 25-50%
can be attributed to medical intervention. Among
patients with established coronary heart disease,
nearly78%of preventedorpostponeddeathsareattri-
butable to medical or surgical intervention.
6
Outstandingmattersremain.Thefirstiswhetherthe
contribution of health care to survival is similar across
population subgroups.In England and Wales substan-
tial improvements in mortality have occurred among
middle aged and older people (aged 50-69) over the
second half of the 20th century, particularly during
the final decades.
7 During this period only modest
improvements in mortality occurred among
20-40 year olds but substantial improvements
occurred among 50-79 year olds. Thus between 1981
and 2000, life expectancy at age 50 increased by 3.
8 years among men and 2.6 years among women.
8 It
is particularly relevant to examine the impact of med-
ical treatment on health outcomes in older people
within the context of evidence that elderly people
may be less likely to receive medical interventions,
perhaps because of uncertainties over trade-offs
between risks and benefit.
9-11 There is also widespread
evidence that socially disadvantaged people and
women are less likely to receive treatments for
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BMJ | ONLINE FIRST | bmj.com page 1 of 11cardiovascular disease compared with their affluent
and male counterparts.
1213 Variations in use of health
care across social groups are difficult to justify if treat-
mentassociatedimprovementsinmortalityaresimilar
across these groups.
Secondly,itcannotbeassumedthatthecontribution
ofhealthcaretoimprovementsindeathfromcoronary
heart disease applies to all the major causes of death.
Strokeisthesecondmostcommoncauseofdeathafter
coronary heart disease in developed countries
14 and
80% of cases occur in over 64s.
15 It shares many of
theriskfactorswithcoronaryheartdiseaseyetitisasso-
ciated with a slower rate of decline in mortality.
7 This
may be because stroke is a syndrome in which the
broadest subcategories are cerebral infarct (about
80%ofcasesandmorecommonwithage)andcerebral
haemorrhage.
1617 Whereas cerebral infarct and coron-
ary heart disease are likely to have a common cause,
the evidence suggests that cerebral haemorrhage has
different causes.
18 Thus, in common with coronary
heart disease, the serum cholesterol level is positively
associated with cerebral infarct but is inversely asso-
ciated with haemorrhagic stroke,
19 and there are
noticeable differences in the pooled relative risks for
the effect of smoking on cerebral infarct (1.92)
20 and
cerebral haemorrhage (1.06).
21 It is possible that expo-
sures in early life could be more important in cerebral
haemorrhage.
18 It is therefore plausible to suggest that
the balance between the contribution of health care
compared with behavioural interventions to health
outcomes may be different for stroke compared with
coronary heart disease. Estimates of treatment effects
for individual interventions for stroke can be obtained
fromrandomisedtrials,butbeneficialeffectstendtobe
lower in routine clinical practice and it cannot be
assumed that the effectiveness of recommended com-
binations of treatment are additive and independent.
Estimations of treatment effects using observational
data from routine care overcome these limitations.
Weanalysedthecontributionofsecondarydrugpre-
vention to stroke survival among adults aged 50 or
morebetween1995and2005usinganationalprimary
care dataset for England. We determined the extent to
which secondary prevention for stroke varies by sex,
age, and socioeconomic circumstances; whether the
association between secondary prevention and one
year mortality after stroke varies between social
groups; and the effect of secondary prevention on
one year mortality by sociodemographic group.
METHODS
We examined individual patient data from primary
care using the health improvement network
database.
22 This database comprises over 15 years of
individual level medical and therapeutic data on 1.99
millionpatientsfrom253generalpracticesacrossEng-
land.
Thehealthimprovementnetworkdatabaseissimilar
to the general practice research database, and about
half of practices in the health improvement network
database also report to the general practice research
database.
23Howeverthehealthimprovementnetwork
databasehastheadvantageofincludinganindicatorof
socioeconomiccircumstancesassociatedwithpatients’
postcodes. Patients’ socioeconomic circumstances are
determined by the area level Townsend index of
deprivation.
24 The index is based on four variables
taken from the 2001 census and available at the output
area level (about 150 households). These variables
(household unemployment, overcrowding, owner
occupation, and car ownership) combine to form an
overall score. The higher the index score, the more
deprived and disadvantaged an area is judged to be.
Scores for the ward of residence of each patient are
ranked and divided into fifths (1 for least deprived, 5
for most deprived). Each patient is then assigned a
Townsend fifth score as a measure of their socioeco-
nomic circumstances.
Study design
We identified practices that had contributed compu-
terised data for at least five years between 1995 and
2005. We included data only from practices that
Data from health improvement network database (314 practices)
Practices in England (n=253)
Excluded practices (n=61)
Outside of England (Wales, Scotland, Northern Ireland)
Excluded practices (n=6)
Missing values for Townsend score
119 practices
113 practices
Patients with a diagnosis of stroke (n=31 770)
Excluded practices (n=134):
  <5 years of adequate and consistent data or record
    keeping (n=72)
  Did not have acceptable mortality rates throughout
    study period (n=62)
Eligible patients analysed (n=12 830):
  Died between 31 and 365 days, completed follow-up (n=1473)
  Censored (alive at end of study period), completed follow-up
    (n=9844)
  Left practice between 31 and 365 day follow-up (n=1513)
Excluded patient records (n=18 940): 
  Missing values for Townsend score (n=939)
  Stroke diagnosis before patient registration or
    practice’s data quality date (n=11 213)
  Incident stroke outside study period (n=2933)
  Did not have at least one year of record keeping from
    patient registration or practice’s data quality date
    (n=2930)
  Patient study exit date preceded study entry date
    (data quality issue) (n=18)
  Patient exit date within 30 days of incident stroke
    (n=414)
  Patient age <50 years (n=493)
Steps taken in selecting practices contributing data to health
improvement network database and patient records for
analysis. *Patients with missing data on age. Data on sex
were excluded before data extract was received
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additional health data record (for example, a blood
pressure measurement), and at least two prescriptions
on average for each patient a year. This ensured inclu-
sion of practices that fully used their computer system
for consultations. We also restricted our sample to
practices with acceptable mortality (based on national
data and the practice’s demographic profile) through-
outthe11yearstudyperiod.
25Theage,sex,anddepri-
vation fifths of included and excluded patients were
similar (see web extra table A).
Weconfinedouranalysestopatientswhowereaged
50 or more and who had a diagnosis of incident stroke
recorded between 1995 and 2005. To ensure that only
patients with incident stroke were examined, we
excluded patients with a stroke before 1995 and
included only patients with at least one year of stroke-
free data before the date of the stroke. Overall we
excluded 1047 patients because they did not meet the
study inclusion criteria or had missing data on Town-
send fifths.
The Read code classification scheme is used to code
medicaldiagnosesinthehealthimprovementnetwork
database.
26Weincludedpatientswithcodesforunspe-
cified stroke, ischaemic (thrombotic or embolic)
stroke, subarachnoid haemorrhage, and intracerebral
haemorrhage.
UK clinical guidelines for the secondary prevention
ofstrokeinprimarycarerecommendappropriatedrug
combinations for ischaemic and haemorrhagic
stroke.
27Thesestatethatpatientswithhighbloodpres-
sure (systolic blood pressure >140 mm Hg, diastolic
blood pressure >85 mm Hg) should receive anti-
hypertensives. In addition, patients with ischaemic
stroke should be given antithrombotics and lipid low-
eringdrugsiftheirtotalcholesterollevelisgreaterthan
3.5 mmol/l. Recent evidence suggests that the benefits
of reducing blood pressure and cholesterol levels are
irrespective of their baseline levels.
2829 Furthermore,
70% of men and 84% of women aged over 50 have
high total cholesterol levels (>5 mmol/l),
30 so most, if
notall,patientswithischaemicstrokewouldbeeligible
to receive lipid lowering drugs and antihypertensives.
Asthisevidencewasavailableonlyforthelatterpartof
the study period we designed two sets of analyses.
Firstly, we assumed that all patients with ischaemic
stroke were eligible to receive antihypertensives and
lipid lowering drugs, as suggested by recent evidence
(inadditiontoantithrombotics).Inthe secondanalysis
we restricted the sample to patients eligible to receive
antihypertensives,asdefinedbytheguidelines.Wedid
notrestrictthesampleonthebasisofcholesterollevels
because of our experience of inconsistency in data
entry on this variable in the health improvement net-
work database.
Drugsinthehealthimprovementnetworkdatasetare
assignedcodesfromtheBritishNationalFormulary.
31We
thereforeusedthesecodestoidentifyallbloodpressure
lowering drugs, lipid lowering drugs, and anti-
thrombotics. Drugs selected for analysis were lipid reg-
ulators,antithrombotics(antiplateletsoranticoagulants),
and antihypertensives, including diuretics, β blockers,
angiotensin converting enzyme inhibitors, calcium
channel blockers, α adrenoceptor blockers, and
adrenergics.
Wedefinedsecondarydrugpreventionasbeingpre-
scribed either antihypertensives plus lipid lowering
drugs plus antithrombotics or antihypertensives plus
lipid lowering drugs.
We assumed that prescriptions provided between 0
and90daysfromtheinitialdateofthestrokediagnosis
were prescribed for the event. This period was chosen
because once discharged from hospital, patients may
be given prescriptions by the hospital pharmacy but
Table 1 |Odds ratio for association between secondary drug prevention and sex, Townsend fifth, and age
Variable
No of
patients
No (%) of patients
receiving secondary
drug prevention*
Univariable model Multivariable model†
Odds ratio (95% CI) P value‡ Odds ratio (95% CI) P value‡
Men 6228 1594 (25.6) 1
<0.001
1
0.07
Women 6602 1372 (20.8) 0.76 (0.70 to 0.84) 0.90 (0.80 to 1.01)
Townsend fifth:
First (least deprived) 3159 748 (23.7) 1
0.36
1
0.44
Second 2829 677 (23.9) 1.01 (0.86 to 1.19) 1.04 (0.88 to 1.23)
Third 2719 590 (21.7) 0.89 (0.75 to 1.06) 0.92 (0.78 to 1.10)
Fourth 2432 546 (22.5) 0.93 (0.74 to 1.17) 0.94 (0.73 to 1.21)
Fifth (most deprived) 1691 405 (24.0) 1.02 (0.78 to 1.32) 1.01 (0.76 to 1.34)
Age group:
50-59 1639 432 (26.4) 1
<0.001
1
<0.001
60-69 2749 820 (29.8) 1.19 (1.00 to 1.42) 1.19 (1.00 to 1.42)
70-79 4319 1155 (26.7) 1.02 (0.85 to 1.22) 1.03 (0.86 to 1.24)
80-89 3387 528 (15.6) 0.52 (0.40 to 0.66) 0.53 (0.41 to 0.69)
≥90 736 31 (4.2) 0.12 (0.08 to 0.19) 0.13 (0.08 to 0.21)
Standard errors adjusted for clustering (113 practices); n=12 830.
*Secondary drug prevention prescribed within 0-90 days of incident stroke.
†Each risk factor (sex, Townsend fifth, age group) adjusted for other factors.
‡Wald test.
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We also had to take account of the drugs being pre-
scribed for conditions other than stroke. To increase
the likelihood that the treatment was related to the
stroke event we chose a cut-off point of 90 days. The
treatmentperiodbeganimmediatelyafterthestroketo
ensure that we included all secondary prevention pro-
vided within primary care.
Lipid lowering drugs are contraindicated in patients
with active liver disease; antiplatelets are contraindi-
catedinpatientswithsevereliverdisease,pepticulcers,
and taking anticoagulants; β blockers are contraindi-
cated in patients with asthma or chronic obstructive
pulmonarydisease;certain antihypertensives (particu-
larly angiotensin converting enzyme inhibitors) may
be contraindicated or cause complications in patients
with chronic renal disease.
32 We carried out sensitivity
analyses after adjustment for evidence of liver disease
only (Read codes A7, 44D, J60-J63, 43B, ZV02B,
ZV02C) at any time before the stroke diagnosis until
90 days from the date of diagnosis. We did not adjust
analyses for asthma, chronic obstructive pulmonary
disease, or chronic renal disease because the availabil-
ity of several classes of antihypertensives allows alter-
native drugs to be prescribed, as recommended in
national guidance.
33 It was unnecessary to adjust for
thoseconditionsforwhichantiplateletsare contraindi-
cated because our definition of secondary prevention
took account of the fact that these drugs might be con-
traindicated. Finally, we did not adjust for coronary
artery disease because of the high colinearity between
drugs used for secondary prevention of stroke and
those used for coronary artery disease.
Patientswhodiedwithin30daysofastrokewerenot
included in the analyses because most (85-90%)
patients with stroke were admitted to hospital
34 for a
mean of 30 days during the period of study.
35 This
exclusion criterion allowed us to examine the associa-
tion between mortality and treatmentprovided by pri-
mary care. Our discussion of mortality within the first
yearassumesthatthepatientsurvivedthefirst30days.
Smokinghasapotentialconfoundingeffectbetween
the social factors measured and stroke mortality.
Patients’ smoking status was defined according to
their closest record to the date of stroke. We cate-
gorised patients whose smoking status was recorded
at any point before to one year after the diagnosis of
incident stroke into several groups: smoker, non-smo-
ker, former smoker before stroke, and former smoker
after stroke. We created a binary smoking variable:
current smoker at stroke date (including former smo-
ker after stroke) compared with not current smoker
(including non-smoker and former smoker before
stroke).
We used registration data to identify patients who
died (all causes). Patient time was calculated from the
31 days after the date of the first record of the stroke to
the date of death, the date that the patient left practice,
the last data collection from the practice, or end of the
study period, whichever came first.
Statistical analysis
To investigate univariable and multivariable associa-
tions between the odds of receiving secondary drug
prevention and sex, age group, and deprivation fifth
(socioeconomic circumstances), we undertook logistic
regression with standard errors adjusted for clustering
by general practice. In the multivariable model we
adjusted each factor for the other factors examined
(sex, age group, and Townsend fifth). A lower than
expectedproportionofpatientsweresmokerssuggest-
ing some misclassification (for example, smokers who
said they were non-smokers). As this could introduce
bias we excluded the variable “smoking status” in the
main analyses but included it in secondary analyses.
To further examine the association between patient
characteristics and appropriate treatment we devel-
opedthreefurtherregressionmodelswiththeoutcome
variable secondary prevention replaced, respectively,
by lipid lowering drugs, antihypertensives, and anti-
thrombotics (all yes or no). In view of the sharp rise
in the use of lipid lowering drugs during the study per-
iod, we also investigated whether the associations for
useoflipidloweringdrugschangedovertimebyfitting
models with a dichotomous time variable (1995-9,
2000-5) and the relevant interaction terms.
We applied the Cox proportional hazard model to
investigate univariable and multivariable associations
between one year mortality and sex, age group, socio-
economic circumstances, and secondary prevention,
adjusted for clustering by general practice. In each
multivariable model each factor was adjusted for all
the other factors examined. The smoking status vari-
able was included in secondary analyses. We created
andtestedinteractiontermsbetweentreatmentandthe
other covariates to investigate potential differential
treatment associations. The Wald test was used to test
for statistical significance. We checked the propor-
tional hazards assumption using Schoenfeld residuals.
We used Stata 9.2 for all analyses.
To quantify the effect of secondary prevention on
mortality we evaluated the probabilities of mortality
within the first year for those social factors of interest
(adjusting for the other social factors) and treatment.
We repeated the analyses having restricted the sample
to patients with blood pressure records and who were
eligible to receive antihypertensives.
Sensitivityanalysesweredonebyincreasingthepre-
scriptionperiodto365daysbecausesome,particularly
elderly, patients may stay in hospital for long periods
after stroke. We repeated the analyses adjusted for the
presenceofliverdisease.Whenweexaminedtheasso-
ciation between patient characteristics and drug treat-
ment, only the model for lipid lowering drugs was
adjusted for liver disease.
RESULTS
Intotal,12830patientsfrom113practicesacrossEng-
landwereincludedinthestudy(figure):11202(87.3%)
had a diagnosis of unspecified stroke, 1019 (7.9%) of
ischaemic stroke, 351 (2.7%) of intracerebral haemor-
rhage, and 258 (2%) of subarachnoid haemorrhage.
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unspecified it was not possible to distinguish those
patients with ischaemic stroke for whom anti-
thrombotic and lipid lowering therapy would be
appropriate.Asstudieshavereportedthatmoststrokes
are ischaemic
17 the analyses assume that all patients
were eligible to receive antihypertensives and lipid
lowering drugs. The results of these analyses are illu-
strated in the tables. In addition we have provided
results that were limited to the 6820 (53.2%) patients
eligibletoreceiveantihypertensives(860patientswere
excluded because they were normotensive and 5150
were excluded because they had no blood pressure
recorded). When the analyses were adjusted for smok-
ingstatus,the11791 (91.9%)patientswitha recordfor
smoking status were included, of whom 1989 (16.9%)
werecurrentsmokers.Overall,221(1.7%)patientshad
a record of liver disease.
Variation in secondary prevention by sex, age group, and
deprivation
Univariableanalyses(table 1)indicatedthatmenwere
more likely to receive secondary prevention than
women (25.6% of men v 20.8% of women). The odds
of receiving secondary prevention decreased for
patients aged over 80: 26.4% of patients aged 50-59
received treatment compared with 15.6% of patients
aged80-89and4.2%aged90ormore.Theproportions
of patients receiving treatment in each Townsend fifth
were similar, ranging from 21.7% to 24.0%.
The differences in the proportions receiving treat-
ment between the age groups persisted in multivari-
able analyses. In particular, the odds for receiving
treatment decreased for the over 80s. Compared with
patientsaged50-59the oddsofreceivingtreatmentfor
those aged 80-89 was 0.53 (95% confidence interval
0.41 to 0.69) and for those aged 90 or more was 0.13
(0.08 to 0.21). After adjustment for age and depriva-
tion, weak evidence showed an association between
sex and receipt of treatment (0.90, 0.80 to 1.01,
P=0.07) and no evidence of variation between Town-
send fifths.
The findings were not changed by adjusting for
smoking status (see web extra table C) or liver disease
(see web extra table F) or by restricting the analysis to
patients eligible to receive antihypertensives. Expand-
ing the prescription period led to the identification of
797 new cases receiving secondary drug prevention,
with similar proportional increases in cases for each
age group. This did not alter the findings.
Overall, 32% of men and 25.7% of women received
lipid lowering drugs, just over 60% of both sexes
received antihypertensives, and 62.3% of men and
60.4% of women received antithrombotics (see web
extratableB).Theoddsofbeingprescribedindividual
drugs varied by age group. There was also some evi-
dence of variation by sex (table 2). Thus there was
strong evidence of a lower probability of receiving
lipid lowering drugs for the over 80s. Compared with
patients aged 50-59 the odds for patients aged 80-89
receiving treatment was 0.44 (95% confidence interval
0.33 to 0.59) and for those aged 90 or more was 0.12
(0.08to0.19).Theseresultswerenotaffectedbyadjust-
ment for liver disease (see web extra table G).
Whentheinteractionbetweenagegroupandperiod
wasexamined,between1995and 1999the differences
between older and younger people were large. For
example, compared with 50-59 year olds the odds of
those aged 80 or more receiving lipid lowering treat-
ment was 0.05 (0.03 to 0.09). Between 2000 and 2005,
Table 2 |Odds ratio for association between lipid lowering drugs, antihypertensive or antithrombotic drugs*, and sex,
Townsend fifth, and age
Variable
Multivariable models†
Lipid lowering drugs Antihypertensive drugs Antithrombotic drugs
Odds ratio (95% CI) P value‡ Odds ratio (95% CI) P value‡ Odds ratio (95% CI) P value‡
Men 1
0.03
1
0.64
1
<0.01
Women 0.88 (0.79 to 0.99) 0.98 (0.88 to 1.08) 0.85 (0.75 to 0.96)
Townsend fifth:
First (least
deprived)
1
0.72
1
0.67
1
0.27
Second 1.03 (0.87 to 1.21) 1.03 (0.91 to 1.15) 1.16 (1.00 to 1.34)
Third 0.94 (0.79 to 1.13) 0.99 (0.86 to 1.13) 1.14 (0.97 to 1.34)
Fourth 1.01 (0.76 to 1.32) 1.05 (0.83 to 1.33) 1.39 (1.03 to 1.88)
Fifth (most
deprived)
0.98 (0.72 to 1.33) 1.12 (0.87 to 1.45) 1.41 (1.02 to 1.95)
Age group:
50-59 1
<0.001
1
<0.001
1
<0.001
60-69 1.13 (0.96 to 1.34) 1.41 (1.21 to 1.63) 2.08 (1.79 to 2.41)
70-79 0.86 (0.70 to 1.05) 1.76 (1.46 to 2.11) 2.87 (2.27 to 3.63)
80-89 0.44 (0.33 to 0.59) 1.53 (1.18 to 1.99) 2.92 (2.09 to 4.09)
≥90 0.12 (0.08 to 0.19) 1.17 (0.87 to 1.57) 2.38 (1.63 to 3.48)
Standard errors adjusted for clustering (113 practices); n=12 830.
*Drugs prescribed within 0-90 days of incident stroke.
†Each risk factor (sex, Townsend fifth, age group) adjusted for other factors.
‡Wald test.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 5 of 11however,thegaphadnarrowed,althougholderpeople
were still lesslikely to receivetreatment: oddsratio for
patients aged 80 or more 0.36 (0.28 to 0.46).
The odds of being prescribedantithrombotics, how-
ever, increased with increasing age. Thus compared
with patients aged 50-59 the odds of patients aged 80-
89 receiving antithrombotics was 2.92 (2.09 to 4.09).
The odds of being prescribed antihypertensives was
also generally higher for older ages, with patients
aged 70-79 having the highest chance of receiving
such drugs (1.76, 1.46 to 2.11).
There was evidence that women were less likely to
receive lipid lowering drugs (0.88, 0.79 to 0.99) and
antithrombotics (0.85, 0.75 to 0.96). The probability
of receiving antihypertensives did not differ between
thesexes.Finally,therewasnoevidenceofadifference
in the probability of receiving any of the three cate-
gories of drugs by socioeconomic circumstances.
When analyses were restricted to patients eligible to
receive antihypertensives, there was evidence that
patients in the most deprived fifth were more likely to
receiveantihypertensives(1.43,1.03to1.98).Thefind-
ings were not altered by adjusting for smoking status
(see web extra table D) or by expanding the treatment
period.
Secondary drug prevention and risk of mortality within first
year
In total, 10.4% of men and 12.5% of women died
between 31 and 365 days after stroke (table 3). Uni-
variable analyses showed that risk of mortality within
the first year was associated with secondary drug pre-
vention,agegroup,socioeconomiccircumstances,and
sex. The risk of mortality was lower in those who
received secondary drug prevention (hazard ratio
0.38, 95% confidence interval 0.31 to 0.46), younger
patients, and men. There was some evidence of an
association with Townsend fifth (P=0.06). The multi-
variable analysis showed similar associations for
receipt of secondary drug prevention (0.50, 0.42 to
0.59), and with age and socioeconomic circumstances.
Thus compared with 50-59 year olds, the risk of mor-
tality increased with each decade: the hazard ratio
among 60-69 year olds was 1.66 (1.24 to 2.23) and
among 80-89 year olds was 5.63 (4.03 to 7.86). There
was some evidence for different survival experiences
byTownsendfifth.Comparedwithpatientsintheleast
deprived fifth, those in the most deprived fifth had an
increased risk of mortality (1.29, 1.07 to 1.55). How-
ever, the adjusted risk of mortality by sex showed
that women had a lower risk of mortality than men
(0.86, 0.77 to 0.96). This was due to the presence of a
largerproportionof women(40.8%) thanmen(23.0%)
aged 80 or more with stroke. The findings were not
altered when adjusting for liver disease (see web extra
table H), restricting the analyses to patients eligible to
receive antihypertensives, expanding the treatment
period, or adjusting for smoking status (see web extra
table E). There was no evidence to indicate a violation
of the proportional hazards assumption.
Effect of secondary drug prevention on risk of mortality
within first year by age and sex
Analyses using the multivariable Cox proportional
hazardsmodel withinteraction terms providedno evi-
dence that the effect of treatment was modified by sex
(P=0.76) or age (P=0.29). There was some evidence
(P=0.02) of a modification by Townsend fifth. How-
ever there was no trend across the deprivation fifths.
Modelbasedestimatesofdyingwithinoneyearsug-
gested that, on average, patients receiving treatment
had a 5.7% probability of death compared with
11.1%ofpatientsnotreceivingtreatment.Thesevalues
changed little by sex and across Townsend fifths.
Younger patients, because of their lower mortality
rate, exhibited little absolute difference in mortality
(2% of treated patients compared with 3.9% of
untreated patients among 50-59 year olds), whereas
older patients exhibited a larger absolute difference
(10.5% of treated patients compared with 20% of
untreated patients among 80-89 year olds).
DISCUSSION
In this national study of nearly 13000 patients aged
50 years or more from 113 practices in primary care,
we found low rates of receipt of secondary drug pre-
vention: only 25.6% of men and 20.8% of women
receivedtreatment.Wealsofoundevidenceofanasso-
ciation of reduced treatment with older age, with the
odds of 80-89 year olds receiving secondary preven-
tion nearly half that of 50-59 year olds. This was
because older people were less likely to receive lipid
loweringdrugs(moresointhelate1990sthantheearly
2000s). This variation in treatment is important
because the receipt of secondary drug prevention for
patients who survived the first 30 days after a stroke
was associated with a 50% reduction in the hazard of
dyingduringthefirstyear.Thisreductionhaddifferent
implications for different age groups as a result of the
underlying increased rates of mortality for older peo-
ple—that is,a 10.5%absolutedifferencein riskofmor-
talityduringthefirstyearfor80-89yearoldscompared
with a 2.0% difference for 50-59 year olds. Crucially
therewaslittleevidencethattheeffectoftreatmentdif-
fered between the social groups examined.
We did, however, find some evidence for different
survival experiences by Townsend fifth and sex that
could not be explained by differences in treatment.
The most socially disadvantaged patients had lower
one year survival than their most advantaged counter-
parts, and women had a higher likelihood of one year
survival than men. The findings were not altered by
adjustmentforsmokingstatusorliverdiseaseorexten-
sion of the prescription period.
Strengths and limitations of the study
We measured the relation between receipt of recom-
mendedcombinationsofdrugtreatmentsandoneyear
mortality within primary care. The size of the benefi-
cial effect of drug treatment combinations in routine
clinical practice has not been previously shown.
Meta-analyses of randomised controlled trials have
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prevention.
36-38 However, treatment effects in routine
clinical practice tend to be lower than in randomised
trials (N Bennett and R Hooker, personal communica-
tion, 1996) and it cannot be assumed that all inter-
ventions have independent effects.
39 A modelling
exercise of the potential effectiveness of combining
multiple interventions (including drugs, dietary modi-
fication, and exercise) estimated that at least 80% of
recurrentstrokesmightbepreventedbyacomprehen-
sive multifactorial approach.
40 This estimate is similar
to that which would be produced by Wald and Law’s
proposed “polypill” for vascular prevention.
41 These
approaches, however, also assumed that all inter-
ventions have independent effects and used estimates
of treatment effects from randomised trials. By using
the health improvement network dataset, which con-
tainswellrecordeddataonprescribing,wewereableto
establishtheeffectononeyearsurvivaloftreatmentin
routine clinical practice and whether this varied
between ages, sex, and socioeconomic circumstances.
Use of this large dataset also enabled the calculation of
precise effect estimates. All patients registered with a
practicewereincludedsoselectionbiasshouldnotbea
problem. We excluded practices which did not fully
use their computer system for consultations and those
withinconsistentnumbersofdeathsforthepracticefor
at least one year during the study period. We also
excludedpatientswhodidnotmeetthestudyinclusion
criteria and those with missing Townsend scores. (The
smallnumbersofpatientswithmissingdataonageand
sexwereexcludedfromthedatasetbeforewereceived
it.) In addition, the health improvement network
database comprises general practices across England,
enablingestimationofnationaltrendsoverallaswellas
in different social groups.
The representativeness and the quality of data from
the health improvement network has been compared
withotherdatabases.Theseshowthatwhencompared
with the quality and outcomes framework, the health
improvement network database contains nationally
representative data for coronary heart disease and dia-
betes (BT Blak, M Thompson, and A Bourke. Ninth
annual conference of the UK Federation of Primary
Care Research Organisations, Liverpool, 2006). The
health improvement network database produces simi-
lar results to the general practice research database
when testing well established epidemiological associa-
tions between diseases and between diseases and
drugs
42 and when detecting disease outcomes,
43 and
the baseline characteristics and levels of recording of
cardiovascular risk factors are similar in the health
improvement network and QResearch databases.
44
However, our study also shares limitations of
research using routinely collected data on patients.
This includes non-standardised coding of date of diag-
nosis for incident stroke and non-standardised and
incomplete coding of stroke subtype, comorbidity,
management, and cause of death. Although we were
able to examine the appropriateness of anti-
hypertensive treatment, incomplete coding of stroke
subtype and a lack of data on lipid levels meant that
we were unable to assess patterns of prescribing by
stroke type. This is relevant because experimental evi-
dence suggests that lipid lowering drugs may not be
indicated after haemorrhagic stroke. This research
Table 3 |Hazard ratio for association between mortality and sex, secondary drug prevention, Townsend fifth, and age
Variable No of patients
No (%) of
deaths*
Univariable models Multivariable model†
Hazard ratio (95% CI) P value‡ Hazard ratio (95% CI) P value‡
Men 6228 650 (10.4) 1
<0.001
1
<0.01
Women 6602 823 (12.5) 1.22 (1.10 to 1.35) 0.86 (0.77 to 0.96)
Secondary drug
prevention:
No 9864 1322 (13.4) 1
<0.001
1
<0.001
Yes 2966 151 (5.1) 0.38 (0.31 to 0.46) 0.50 (0.42 to 0.59)
Townsend fifth:
First (least
deprived)
3159 326 (10.3) 1
0.06
1
0.05
Second 2829 344 (12.2) 1.20 (1.02 to 1.41) 1.16 (0.99 to 1.36)
Third 2719 325 (11.9) 1.18 (0.98 to 1.42) 1.11 (0.93 to 1.32)
Fourth 2432 268 (11.0) 1.07 (0.85 to 1.35) 1.07 (0.88 to 1.30)
Fifth (most
deprived)
1691 210 (12.4) 1.22 (1.00 to 1.50) 1.29 (1.07 to 1.55)
Age group:
50-59 1639 54 (3.3) 1
<0.001
1
<0.001
60-69 2749 146 (5.3) 1.63 (1.22 to 2.18) 1.66 (1.24 to 2.23)
70-79 4319 407 (9.4) 2.95 (2.18 to 3.99) 2.99 (2.20 to 4.06)
80-89 3387 586 (17.3) 5.78 (4.23 to 7.91) 5.63 (4.03 to 7.86)
≥90 736 280 (38.0) 14.99 (10.8 to 20.77) 14.17 (9.91 to 20.26)
Standard errors adjusted for clustering (113 practices), n=12 830.
*Deaths within 31-365 days of incident stroke.
†Each risk factor (sex, secondary drug prevention, Townsend fifth, age group) adjusted for other factors.
‡Wald test.
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so could not have influenced clinical decision
making,
45 (although observational evidence of the
inverse association between serum cholesterol levels
andhaemorrhagicstrokewasavailableduring theper-
iodstudied).Althoughtheavailabilityofdataonstroke
subtypes and lipid levels would have been valuable,
haemorrhagic stroke occurs in a few patients with
stroke so is unlikely to have had a major impact on
our results. Had we been able to distinguish between
subtypes, any social variations found in use of lipid
lowering and antiplatelet drugs would have to be
viewed in the context of differences in risk factors for
the subtypes of stroke and social variations in the pre-
valenceoftheseriskfactors.
18Hadwebeenabletotake
accountoflipidlevelsintheanalyses,thiswouldnotbe
expected to alter the age effects because of the high
total cholesterol levels observed in men and women
after age 45.
3046 Inaccurate and missing data on blood
pressure levels may also explain the results of our sub-
group analyses for antihypertensive treatment. Only
221 (1.72%) patients had a record of liver disease.
This proportion of patients would not have been
expected to have an impact on the results. Missing
data may account for the small number of patients
with recorded liver disease. A small retrospective ana-
lysis of primary care data from the United States sug-
gests that the prevalence of chronic liver disease was
3.7%.
47
Overall, 92% of patients had smoking status
recorded within five years of stroke. The proportion
of patients who were current smokers was lower than
expected (16.9% compared with 60% of patients who
in other studies reported being current or former
smokers).
1648 This may be due, for example, to a smo-
ker giving their smoking status as non-smoker. This
potential misclassification could introduce bias, hence
the results adjusted for smoking should be interpreted
with caution. That said, the results after adjustment for
smoking status are plausible; given the association of
smoking with deprivation,
49 adjustment for smoking
would be expected to reduce any association between
deprivationandstrokemortality.Inthiscasetherewas
nostrongassociationbetweendeprivationandmortal-
ity before adjustment and when we adjusted for smok-
ing there remained no strong association.
Although data on cause of death were incomplete,
data on all cause mortality were available. Such data
are commonly used in preference to data on disease
specific mortality because of known incompleteness
and inaccuracies in recording cause of death and
because other research has shown that the most com-
moncauseofdeathinthe firstyearafterstrokewasthe
index stroke (64%).
50
Severalothermethodologicalissuesneedtobetaken
into account. Firstly, to limit overlap between treat-
ment and outcome periods (0-90 days and
31-365 days, respectively), we decided to use the
90 day cut-off point for prescriptions in our main ana-
lysis. This minimised the possibility of immortal time
bias or survival bias, which can lead to overestimation
of treatment effect in epidemiological studies.
51 The
remaining 60 day overlap between the treatment and
outcome periods could nevertheless have led to some
overestimationoftreatmenteffects.Secondly,we used
a well established method of assigning socioeconomic
characteristicsbasedonareaofresidence.Thismethod
rests on the assumption that people conform to the
socioeconomic profile of their residential area. We do
therefore recognise that misclassifications of indivi-
duals’ socioeconomic circumstances can cause under-
estimates or overestimates of the relation between
socioeconomic circumstances and treatment use and
mortality. Thirdly, we confined our survival analyses
tooneyearafterstrokeforanalyticalreasons.Weused
the Cox proportional hazards model, which assumes
that the proportional effect of any variable on risk of
mortality does not change over time. This assumption
isnotlikelytoholdoverlongerperiods(morethanone
year) since the effect of treatment is maximal in the
shortterm.However,thislimitationisjustifiedbecause
the risk of death is greatest in the first year after stroke.
Finally, we cannot assume that prescribing secondary
drug prevention during the first year after stroke is
maintained in the longer term.
Comparison with other studies
We found low rates of prescribing of effective second-
ary prevention in patients after stroke. Another analy-
sis of English data (collected in south London during
the 1990s) found higher treatment rates: 72.9% of
patients considered appropriate for antithrombotics
and 70.5% considered appropriate for anti-
hypertensives actually received them.
52 A strength of
this study was its ability to classify the subtype of
stroke. However, it was a small local study of 457
patients and limitations about misclassification of
patients’ appropriateness for preventive therapy were
noted.A much largerstudy of nearly 45000 Canadian
patients with stroke reported low rates of aspirin use
(38.1% in men and 35.6% in women).
53 In another
Canadian study of over 390000 patients aged
66 years or more and with a history of cardiovascular
disease only 19.1% were prescribed statins.
54
Although there is a considerable literature on social
differences in treatment use across a diverse range of
conditions,
1213 few studies have examined care after
stroke. The south London study examined manage-
ment using antithrombotics and antihypertensives
three months after ischaemic stroke. It found no asso-
ciationsbetweentreatmentuse andage,social class,or
sex.
52Italsofailedtoshowsignificantdifferencesinthe
recurrence free survival rate between patients who did
and did not receive antithrombotics and anti-
hypertensives after stroke. A much larger national
study of prescribing lipid lowering drugs in primary
care for coronary heart disease found a reduced like-
lihood of receiving such drugs with increasing age (as
in our study) and in women. A weak socioeconomic
gradient was also detected.
55 In addition, a Swedish
national study of patients after stroke found that, in
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thrombotics less often than men.
56
Our results are in line withprevious research,which
has documented better one year survival in older
women than in elderly men.
535758 Other research has
also found lower survival among socially disadvan-
taged groups.
1459 The mechanisms through which
socioeconomic circumstances affect stroke outcomes
areunclear.Ourfindingsofthelackofasocialgradient
in secondary prevention raises questions about the
extent to which the social gradient can be explained
by social variations in stroke severity (which is also
socially patterned) and in the maintenance of
unhealthy behaviours. A high prevalence of risk fac-
torsforstroke(bloodpressure,smoking,diabetes,phy-
sical inactivity, obesity) in disadvantaged groups has
been widely reported.
14 However estimates vary as to
howmuchofthedifferenceinstrokeoutcomebysocio-
economic circumstances can be accounted for by var-
iations in prevalence of risk factors.
Other research that has tackled the question of the
benefitsoftreatmentamongolderpeopleisinlinewith
our findings. A meta-analysis of trials including
patients aged 65 to 82 found that lipid lowering drugs
reduce all cause mortality in elderly people.
36 Extra-
polation to older patients in the “real world” is sup-
ported by observational data, which showed that
olderpatientsattainedagreaterabsoluteriskreduction
than younger patients. In addition, the incidence of
adverse effects was similar in patients under 65 and
over 65.
6061 Moreover, the cost effectiveness ratio has
beenshowntobefavourableinelderlypeoplebecause
they have a higher risk of mortality and morbidity.
Finally, the magnitude of relative risk reduction for
mortality or major morbidity was similar between the
sexes.
Implications and conclusions
The enduring interest in McKeown’s ideas can be
explained by the ongoing relevance of the question
that underlies them. This concerns the importance of
medical interventions, compared with social, political,
and economic measures on health status and inequal-
ities in health. A large body of research suggests that
broad measures to redistribute resources are required
to improve health and reduce inequalities in health.
62
However our findings on the contribution of medical
careacrosspopulationsubgroupsaddstotheliterature
in this area,
2-6 which suggests that medical inter-
ventions and social change should be viewed not as
opposing choices but as complementing each other.
1
It is reassuringthat, in contrast with the evidence for
other conditions, this national study of patients after
stroke did not find that socially disadvantaged patients
were less likely to receive treatment than their more
affluent counterparts. Indeed, we report increased use
of antiplatelets among certain social groups (older and
more deprived patients). This is likely to be explained
inpartbytheoverthecounteravailabilityofaspirinfor
people who are not eligible for free prescriptions but
can afford to pay.
Of more concern is the finding of under-use of lipid
lowering therapies among elderly people. The low
treatment rates may in part be explained by the fact
that the first national clinical guidelines for stroke
were not published until half way through the period
under study. It may also be that doctors who care for
patients with multiple comorbidities focus on these
ratherthanonsecondaryprevention.Howeverneither
oftheseexplanationsaccountfortheunder-useoflipid
lowering drugs only, which suggests that this may be
duetothepressurethatexpensivelipidloweringdrugs
have on the primary care budget. Alternatively, varia-
tions in the use of evidence based therapies may be
appropriateiftheyaresecondarytovariationsineffec-
tiveness,costeffectiveness,orthelikelihoodofadverse
consequences and of adherence to treatment. It has
been suggested that these factors may explain under-
use in elderly people.
63 Thus doctors may have con-
cerns about the generalisability of results from clinical
trialto olderpatientswith comorbidities. However the
relativesurvivalbenefitsassociatedwithlipidlowering
drugs have been shown across multiple subgroups,
including elderly patients.
54 Furthermore, the rate of
severecomplicationshasbeenshowntobelow.
54Doc-
tors may also be reluctant to prescribe therapies to
patients thought unlikely to adhere to treatment—for
example, elderly patients exhibiting cognitive, func-
tional, or social decline. However we found an
increased likelihood of being prescribed anti-
hypertensive and antiplatelet treatments with increas-
ing age, so concerns aboutadherence to lipid lowering
drugs alone are an unlikely explanation. Moreover,
analysis of a database of British men with stroke
found that concerns about adherence did not seem to
explainlowratesofmedication
64andthereisevidence
of good compliance rates in elderly patients.
65 Finally,
lipid lowering drugs for secondary prevention in
elderly people have been shown to be cost effective.
66
Thus the evidence suggests that concerns about the
trade-off between benefits and risks in elderly people
may be exaggerated and that one year survival benefit
is not modified by age. Therefore under-treatment of
older people cannot be justified, unless it is explained
by informed patient choice.
The delivery of effective secondary prevention after
stroke is primarily the concern of primary care. Such
inequalitiesmustthereforebeaddressediftheUKgov-
ernmentistofulfilitscommitmenttoreducinginequal-
ities in health by improving access to primary care.
Recent evidence suggests that the introduction of pri-
mary care performance indicators may contribute to
the generation of more equitable health care.
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